Health authorities and the Alzheimer Society of Ontario are calling for urgent government intervention to expand diagnostic capacity and secure public funding for new Alzheimer’s disease-modifying therapies. Without rapid implementation of a coordinated dementia care pathway, patients may face delays of up to 18 months before accessing these emerging treatments, Global News reported.
The push for systemic reform comes as Health Canada has approved two significant new therapies: lecanemab (marketed as Leqembi by Eisai Co. and Biogen) and donanemab (marketed as Kisunla by Eli Lilly). While these drugs represent a clinical milestone, their efficacy is strictly tied to the timing of intervention. Because these treatments target the underlying pathology of Alzheimer’s rather than just managing symptoms, they are only indicated for patients in the very early stages of the disease.
- The Window of Opportunity: These therapies are designed for mild cognitive impairment or early-stage Alzheimer’s; once the disease progresses to later stages, they are no longer effective or safe.
- The Diagnostic Bottleneck: Access to medication is contingent on a formal diagnosis, which currently faces significant delays due to limited specialist availability and diagnostic infrastructure.
- Systemic Barriers: Beyond the drug itself, patients require ongoing medical monitoring, including regular MRI scans and infusion services, which may be difficult to access in rural or lower-income areas.
Disease-Modifying Therapies Slow Cognitive Decline Rates
The arrival of lecanemab and donanemab begins a shift toward disease-modifying therapies. These therapies aim to slow the rate of cognitive decline rather than providing a total cure.
However, the clinical utility of these drugs is governed by a “ticking clock.” Dr. Eric Smith, director of the Cognitive Neurosciences Clinic at the University of Calgary, noted that the treatments are only effective and safe when the disease is recognized in its earliest, most manageable stages. This creates a high-stakes dependency on the speed of the healthcare system’s diagnostic response.
The current system for drug access in Canada is complex. While the Canada Drug Agency has recommended public reimbursement for lecanemab and issued a positive draft recommendation for donanemab, the actual rollout depends on provincial and territorial negotiations. Each jurisdiction must determine pricing and decide whether to include these high-cost therapies in their respective public drug plans.
| Therapy Name | Manufacturer | Primary Indication | Regulatory Status (Canada) |
|---|---|---|---|
| Lecanemab (Leqembi) | Eisai Co. / Biogen | Early-stage Alzheimer’s | Health Canada Approved |
| Donanemab (Kisunla) | Eli Lilly | Early-stage Alzheimer’s | Health Canada Approved |
Systemic Gaps in the Canadian Dementia Care Pathway
The Alzheimer Society of Ontario has identified a lack of a structured “corridor” for dementia care, contrasting it sharply with the established protocols used in oncology. In cancer care, a diagnosis typically triggers an immediate, coordinated transition into specialized treatment. In contrast, dementia patients often face a fragmented process of identifying symptoms, finding specialists, and securing long-term monitoring.
Ngozi Iroanyah, director of health equity and access with the Alzheimer Society of Ontario, highlighted that the current “pathway” is insufficient for the requirements of new drug therapies. The specialized nature of these treatments requires strong infrastructure, including:
- Coordinated dementia-care networks.
- Expanded capacity for early-stage diagnostic testing.
- Consistent access to MRI monitoring to manage potential side effects.
- Reliable infusion services for drug administration.
These requirements present a significant challenge for geographic equity. Patients in rural areas or those from lower socioeconomic backgrounds may face wait times of 18 to 24 months just to receive an initial diagnosis, effectively disqualifying them from the window of efficacy for these new drugs.
Governmental Responses to Emerging Alzheimer’s Therapies
Provincial and federal governments have signaled they are preparing for the shift in dementia care, though the timeline for implementation remains uncertain. In Alberta, the Ministry of Primary and Preventative Health Services stated it is working with Alberta Precision Laboratories to ensure testing, patient eligibility, and monitoring processes are established.
In Ontario, the Ministry of Health noted that the province has made “record investments” in dementia care, including $4.1 million to expand support services, while emphasizing that all new therapies undergo rigorous, evidence-based reviews before being integrated into the system. At the federal level, Health Minister Marjorie Michel’s office indicated that the government is utilizing advice from the Ministerial Advisory Board on Dementia to identify opportunities for improved care and prevention.
Consult Medical Professionals for Specific Cognitive Decline Symptoms
These new therapies are not universal treatments for all forms of cognitive decline. They are specifically indicated for dementia caused by Alzheimer’s disease. Patients should consult a medical professional if they experience:
- Sudden or progressive changes in memory, language, or problem-solving abilities.
- Disruptions in behavior or thinking that exceed what is considered normal for aging.
- Difficulty performing routine daily tasks.
While medical advancements offer new hope, experts like Sylvia Villeneuve, director of the Centre for Studies on Prevention of Alzheimer’s Disease in Quebec, emphasize that clinical intervention must be paired with preventative lifestyle measures. Reducing risk factors through increased physical activity, cognitive engagement, and social connection remains a critical component of long-term brain health.
References
- Alzheimer Society of Ontario
- Health Canada
- Canada Drug Agency
- University of Calgary, Cognitive Neurosciences Clinic
